Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DanaherXSWX:DHR +0.97%79 Equity-to-Asset is 0.57 as of Jun. 2026, which is at its 10-year median of 0.57. GuruFocus rates XSWX:DHR with a GF Score™ of 79/100 and a GF Value™ of CHF193.68. The stock has 4 warning signs investors should review. Among 211 Medical Diagnostics & Research companies, Danaher ranks worse than 52.13% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Danaher's Total Stockholders Equity for the quarter that ended in Jun. 2026 was CHF42,028 Mil. Danaher's Total Assets for the quarter that ended in Jun. 2026 was CHF73,829 Mil.
Therefore, Danaher's Equity to Asset Ratio for the quarter that ended in Jun. 2026 was 0.57.
The historical rank and industry rank for Danaher's Equity-to-Asset or its related term are showing as below:
XSWX:DHR'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.45 Med: 0.57 Max: 0.64
Current: 0.57
During the past 13 years, the highest Equity to Asset Ratio of Danaher was 0.64. The lowest was 0.45. And the median was 0.57.
XSWX:DHR's Equity-to-Asset is ranked worse than 52.13% of 211
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.59
vs XSWX:DHR: 0.57
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Danaher Equity-to-Asset Related Terms
Danaher Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Danaher's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:DHR vs TMO, IDXX, A: Equity-to-Asset Comparison
For the Diagnostics & Research subindustry, Danaher's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Danaher Equity-to-Asset vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Danaher's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Danaher's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Danaher's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Danaher (XSWX:DHR) has a Equity-to-Asset of 0.57 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Danaher and its competitors. This is near median its historical median of 0.57. Over the past decade, Danaher's Equity-to-Asset has ranged from 0.45 to 0.64. According to the industry distribution chart, Danaher ranks #110 out of 211 companies in the Medical Diagnostics & Research industry, placing it in the top 52.1%.
Is Danaher's Equity-to-Asset too high?
Danaher's current Equity-to-Asset of 0.57 is near median its 10-year median of 0.57. Over the past 10 years, this metric has ranged from a low of 0.45 to a high of 0.64. The Medical Diagnostics & Research industry median Equity-to-Asset is 0.59. Danaher's value of 0.57 is 3.4% below this industry median. Based on the distribution chart, Danaher ranks #110 out of 211 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Danaher has a GF Score™ of 79/100, reflecting its overall financial health beyond just this single metric.
How does Danaher's Equity-to-Asset compare to TMO and IDXX?
According to the Medical Diagnostics & Research industry distribution chart, Danaher ranks #110 out of 211 companies for Equity-to-Asset. This places Danaher in the lower half of its industry. The industry median Equity-to-Asset is 0.59. Danaher's value of 0.57 is 3.4% below this benchmark. Historically, Danaher's own Equity-to-Asset has ranged from 0.45 to 0.64 over the past decade. While the company's 10-year median is 0.57 vs. the industry median of 0.59, Danaher has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Diagnostics & Research company?
The median Equity-to-Asset among Medical Diagnostics & Research companies is 0.59, based on 211 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Danaher's current Equity-to-Asset of 0.57 is 3.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Danaher and its competitors. For the Medical Diagnostics & Research industry, the median Equity-to-Asset is 0.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Danaher's current Equity-to-Asset is 0.57, which is near median its own 10-year median of 0.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Danaher stock overvalued right now?
Danaher (XSWX:DHR) has a current Equity-to-Asset of 0.57. The stock's GF Value™ is CHF193.68, compared to a current price of CHF158.80 — trading 18% below its estimated fair value. The current Equity-to-Asset is 0.57, which is near median its 10-year median of 0.57 and 3.4% below the Medical Diagnostics & Research industry median of 0.59. Danaher's overall GF Score™ is 79/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Danaher (XSWX:DHR), the current Equity-to-Asset is 0.57 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Danaher (XSWX:DHR) Overvalued in 2026?
Based on GuruFocus' analysis, Danaher stock appears to be undervalued.
The current stock price of CHF158.80 is trading 18% below its estimated GF Value™ of CHF193.68.
Key valuation signals for XSWX:DHR:
Equity-to-Asset: 0.57 (near median its 10-year median of 0.57)
GF Value™: CHF193.68 vs. price of CHF158.80 (18% below fair value)
Industry Position: 3.4% below the Medical Diagnostics & Research median (#110 of 211)
No single metric tells the full story. See the XSWX:DHR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life sciences and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.
79GF Score
Get the complete analysis for XSWX:DHR
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:DHR has been successfully added to your 
